Zhengye Biotechnology Holding Ltd. (ZYBT)
NASDAQ:ZYBT
Want to see ZYBT full AI Analyst Report?
Top Page
Zhengye Biotechnology Holding Ltd.
(NASDAQ:ZYBT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.97
▼(-14.60% Downside)
Action:ReiteratedDate:05/07/26
The score is held down primarily by weak financial performance in 2025 (sharp revenue decline and a large net loss) alongside materially weaker cash generation. Technicals are neutral-to-weak with longer-term downtrend signals, while valuation metrics provided (P/E of 0.000 and no dividend yield) do not offer clear support.
Positive Factors
Moderate leverage and sizable equity
A debt-to-equity ratio near 0.30 combined with roughly $249.8M of equity provides a durable capital cushion. Moderate leverage preserves financial flexibility to fund operations, R&D or restructuring through a loss cycle, keeping solvency risk manageable over months.
Negative Factors
Sharp revenue decline and margin collapse
A drop from $186.4M to $116.4M and a swing to roughly -60% net margin in 2025 reflect a deep, multi-year demand or pricing deterioration. Sustained revenue contraction and margin erosion materially reduce internal reinvestment capacity and pressure the viability of the current business model over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate leverage and sizable equity
A debt-to-equity ratio near 0.30 combined with roughly $249.8M of equity provides a durable capital cushion. Moderate leverage preserves financial flexibility to fund operations, R&D or restructuring through a loss cycle, keeping solvency risk manageable over months.
Read all positive factors
Zhengye Biotechnology Holding Ltd. (ZYBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.80M
Dividend YieldN/A
Average Volume (3M)871.70K
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue Growth-37.53%
EPS Growth-717.42%
CountryUS
Employees278
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,965,000
10 Day Avg. Volume198,467
30 Day Avg. Volume871,704
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhengye Biotechnology Holding Ltd. Business Overview & Revenue Model
Company Description
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its pr...
Zhengye Biotechnology Holding Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 116.36M | 186.36M | 211.65M | 260.27M | 214.07M |
| Gross Profit | 23.87M | 91.30M | 129.85M | 153.52M | 125.39M |
| EBITDA | -42.52M | 42.60M | 72.10M | 85.55M | 70.12M |
| Net Income | -69.78M | 11.31M | 31.46M | 46.73M | 38.96M |
Balance Sheet | |||||
| Total Assets | 436.47M | 493.25M | 499.89M | 519.67M | 445.28M |
| Cash, Cash Equivalents and Short-Term Investments | 51.89M | 20.04M | 16.30M | 9.75M | 6.28M |
| Total Debt | 75.08M | 86.43M | 89.85M | 64.88M | 30.00M |
| Total Liabilities | 129.76M | 140.71M | 160.62M | 162.81M | 126.44M |
| Stockholders Equity | 249.85M | 283.96M | 272.85M | 296.50M | 267.47M |
Cash Flow | |||||
| Free Cash Flow | 703.00K | 13.27M | 36.58M | -9.99M | 5.41M |
| Operating Cash Flow | 13.33M | 41.05M | 48.18M | 17.34M | 31.81M |
| Investing Cash Flow | -12.63M | -27.66M | -11.77M | -27.33M | -26.27M |
| Financing Cash Flow | 32.31M | -22.13M | -18.98M | 13.46M | -3.05M |
Zhengye Biotechnology Holding Ltd. Technical Analysis
Negative
1.13
Price Trends
6.15
Negative
6.22
Negative
Market Momentum
-1.00
Negative
35.40
Neutral
14.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZYBT, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 2.63, below the 50-day MA of 6.15, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.00 indicates Negative momentum. The RSI at 35.40 is Neutral, neither overbought nor oversold. The STOCH value of 14.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZYBT.
Zhengye Biotechnology Holding Ltd. Risk Analysis
Zhengye Biotechnology Holding Ltd. disclosed 66 risk factors in its most recent earnings report. Zhengye Biotechnology Holding Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zhengye Biotechnology Holding Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $10.80M | ― | 4.06% | ― | -37.53% | -717.42% | |
46 Neutral | $1.59M | -1.53 | 2.66% | ― | -22.44% | -100.02% | |
45 Neutral | $21.37M | -1.06 | -43.00% | ― | -8.49% | 72.59% | |
| ― | $4.33M | -0.28 | -9999.00% | ― | ― | 85.99% |
* Healthcare Sector Average
ZYBT
Zhengye Biotechnology Holding Ltd.
0.99
-10.54
-91.45%
CPHI
China Pharma Holdings
0.53
-1.34
-71.82%
SXTC
China SXT Pharmaceuticals
1.76
-283.24
-99.38%
BGM
Qilian International Holding Group Limited
0.30
-10.69
-97.31%
UPC
Universe Pharmaceuticals
2.82
-2.27
-44.58%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.78
-5.67
-87.91%
Zhengye Biotechnology Holding Ltd. Corporate Events
Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM
Mar 25, 2026
On March 24, 2026, Zhengye Biotechnology Holding Limited held its Annual General Meeting of Shareholders in Jilin City, with investors also able to attend virtually. Shareholders representing a substantial majority of the 47.39 million outstanding...
Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM
Feb 23, 2026
On February 18, 2026, Zhengye Biotechnology Holding Limited announced that independent director Wenbin Wang resigned from the board and its key committees, including his role as chair of the compensation committee, citing personal reasons and conf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.